Question 73

Ventolin HFA and Xopenex HFA may lead to therapeutic duplication.

Both Ventolin HFA and Xopenex HFA are bronchodilators used to relieve symptoms of asthma and other respiratory conditions. Prescribing both can result in therapeutic duplication, as they serve similar purposes in managing bronchospasm.

A) Spiriva Respimat and Dulera

Spiriva Respimat is a long-acting anticholinergic, while Dulera is a combination of a corticosteroid and a long-acting beta agonist. These medications work through different mechanisms and are not considered duplicates, as they target different pathways in managing respiratory conditions.

B) Flovent HFA and Incruse Ellipta

Flovent HFA is an inhaled corticosteroid, and Incruse Ellipta is a long-acting anticholinergic. Similar to the previous example, these medications are used for different purposes in asthma and COPD management, and thus do not represent therapeutic duplication.

C) Ventolin HFA and Xopenex HFA

Both Ventolin HFA and Xopenex HFA are short-acting beta agonists prescribed for the quick relief of bronchospasm. Using them together would result in therapeutic duplication, as they provide similar therapeutic effects, potentially increasing the risk of side effects without added benefit.

D) Serevent Diskus and Atrovent HFA

Serevent Diskus is a long-acting beta agonist, whereas Atrovent HFA is a short-acting anticholinergic. These medications are used in different contexts and do not overlap significantly in their therapeutic action, making them not a concern for therapeutic duplication.

Conclusion

The identification of Ventolin HFA and Xopenex HFA as the correct answer highlights the importance of avoiding therapeutic duplication in patient care. Both medications function similarly, and their concurrent use could lead to unnecessary medication burden and increased risk of adverse effects. In contrast, the other options consist of medications that serve distinct roles in treatment, thereby avoiding duplication concerns.